3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Myeloid
1
Lymphoid
1
Classical hematology
1
Conditions
Anemia
64
Neoplasms
38
Venous Thromboembolism
29
Leukemia
21
Anemia, Refractory, with Excess of Blasts
20
Myelodysplastic Syndromes
19
Lymphoma
14
Thrombocytopenia
13
Multiple Myeloma
12
Leukemia, Myelomonocytic, Chronic
12
Venous Thrombosis
11
Pulmonary Embolism
11
Febrile Neutropenia
11
Breast Neoplasms
10
Myeloproliferative Disorders
9
Lymphoma, Non-Hodgkin
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Neoplasms, Plasma Cell
8
Lymphoma, Follicular
8
Leukemia, Myeloid, Acute
8
Primary Myelofibrosis
6
Neutropenia
6
Hodgkin Disease
6
Hemophilia A
6
Lung Neoplasms
5
Anemia, Refractory
5
Waldenstrom Macroglobulinemia
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Precancerous Conditions
4
Lymphoproliferative Disorders
4
Interventions
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hemorrhagic Disorders
×
Classical hematology
×
Clear all
NCT02055781
2021-11-18
PAC326
CTI BioPharma
Phase 3
Terminated
311 enrolled
12 charts